XNCR News and Press, Xencor Inc.

2026-03-05 10:13:32 ET More on Xencor, AstraZeneca PLC AstraZeneca: Q4 Earnings Analysis - Ticks The Boxes, Upgrading To Buy AstraZeneca PLC (AZN) Q4 2025 Earnings Call Transcript AstraZeneca PLC 2025 Q4 - Results - Earnings Call Presentation China drug licen...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion Pharmaceuticals, Inc. (the “Licensee”) informed Xencor, Inc. (the “Company”) that i...

Evertec Inc. (EVTC) is expected to report $0.81 for Q4 2025 BioCryst Pharmaceuticals Inc. (BCRX) is expected to report $0.06 for Q4 2025 FTI Consulting Inc. (FCN) is expected to report $1.38 for Q4 2025 Arbe Robotics Ltd. (ARBE) is expected to report $-0.1 for Q4 2025 Aclaris Ther...

2026-02-25 17:41:17 ET More on Xencor Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942 Incyte marks late-stage trial win for Xencor-partnered lymphoma therapy Incyte announces EU approval of Xencor-partnered lymphoma therapy Seeking Alpha...

-- XmAb819, novel first-in-class ENPP3 x CD3 T-cell engaging bispecific antibody, Phase 1 dose expansion in CRC, NSCLC and pRCC open to enrollment; on track to present clinical data to support a recommended Phase 3 dose in ccRCC in 2H26 -- -- Final results from healthy-volunteer study of ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at multiple upcoming investor conferences: TD Cowen 46th Annual Health Care C...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced corporate priorities and 2026 pipeline advancement milestones for its clinical-stage portfolio of novel XmAb® drug cand...

2026-01-05 10:19:29 ET More on Incyte, Xencor Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942 Tracking Baker Brothers Portfolio - Q3 2025 Update Incyte Corporation (INCY) Presents at The 67th American Society of Hematology (ASH) Annual Meeting - Sli...

2026-01-01 07:14:57 ET ... Read the full article on Seeking Alpha For further details see: Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942

2025-12-17 11:52:55 ET More on Incyte, Xencor Tracking Baker Brothers Portfolio - Q3 2025 Update Incyte Corporation (INCY) Presents at The 67th American Society of Hematology (ASH) Annual Meeting - Slideshow Incyte Corporation (INCY) Discusses mutCALR Data and Therap...